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Abstract
Background: Pancreatic cancer has a dismal prognosis with 5-year overall survival rate of around 5%. Although
surgery is still the best option in operable cases, majority of the patients who present in locally advanced stages are
deemed inoperable. Novel approaches are therefore needed for the management of around 80% of these inoperable
locally advanced pancreatic cancers (LAPC). Hyperthermia (39–43 °C) is a potent radiosensitizer and further enhances
the action of gemcitabine, also a known radiosensitizer. Thus through triple sensitization, a combination of
hyperthermia, radiotherapy and gemcitabine could be expected to improve the therapeutic outcomes in LAPC.
Methods: This phase II randomized trial, HEATPAC in unresectable LAPC, explores the feasibility and efficacy of concurrent
thermochemoradiotherapy (HTCTRT) over chemoradiotherapy (CTRT) alone with pre- and post-intervention FOLFIRINOX at
standard dosage and schedule. Following 4 cycles of neoadjuvant FOLFIRINOX, patients with no metastasis and absence of
gross peritoneal carcinomatosis would be randomized to either (a) control arm: concurrent CTRT with gemcitabine
(400 mg/m2, weekly ×6) or (b) study arm: locoregional hyperthermia (weekly ×6 during radiotherapy) with concurrent CTRT
(same as in control arm). All patients would receive simultaneous-integrated boost intensity-modulated radiation therapy to
doses of 56Gy and 50.4Gy to the gross and clinical target volumes respectively delivered in 28 fractions over 5.5 weeks.
Deep locoregional hyperthermia would be administered weekly and monitored with real-time intraduodenal multisensor
thermometry probe. A temperature of 40–43 °C for 60 min would be aimed for each hyperthermia session. On completion
of CTRT/HTCTRT, patients of both groups would receive an additional 8 cycles of FOLFIRINOX.
Discussion: The expected 1-year baseline overall survival with CTRT alone is considered as 40%. With HTCTRT, a survival
advantage of +20% is expected. Considering α= 0.05 and β= 0.80 for sample size computation, a total of 86 patients
would be equally randomized into the two treatment groups. This phase II study if found to be safe and effective, would
form the basis of a future phase III randomized study.
Trial registration: The trial has been registered with the ClinicalTrials.gov (NCT02439593). The study has been approved by
the Ethical Commissions of Basel and Zurich and is open for patient recruitment.
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Background
Locally advanced pancreatic cancers: a lethal disease
Worldwide pancreatic cancer is the 7th leading cause of
death and has a fatal prognosis with 5-year survival rate
of less than 5% [1–5]. Globally around 340,000 cases are
diagnosed each year. As per the GLOBOCAN 2012, the
incidence and the mortality rates of pancreatic cancers
even in Europe are nearly similar at 6.8 and 6.6 per
100,000 respectively, indicating that nearly all diagnosed
pancreatic cancers carry a lethal prognosis [5, 6]. The fatal
consequences of pancreatic cancers is aptly summarized by
D. Schrag in a recent editorial in JAMA as, “If cancer is the
emperor of all maladies, then pancreatic adenocarcinoma is
the ruthless dictator of all cancers” [2].
Despite advances in chemo-radiation and advent of
newer systemic agents, outcome in patients with primary
pancreatic adenocarcinoma has not changed significantly
over the last decades. Complete surgical resection is still
the only curative therapeutic option. However, at
diagnosis, merely 10–20% of patients are candidates for
surgical resection, with only 4% expected to undergo
radical surgery. 40% of the patients are known to present
in advanced stages. Despite the best combination
chemotherapy (CT) or chemoradiotherapy (CTRT), 30%
of these patients die due to local progression of disease
without any distant metastasis [1–4].
Possible therapeutic approaches in locally advanced
pancreatic cancers
CT alone or CTRT has been generally accepted as the
standard therapeutic approach for patients with locally
advanced pancreatic cancers (LAPC). In those without
metastasis, neoadjuvant CT before a definitive CTRT has
been used [1–4]. The role of CTRT was initially defined by
Gastrointestinal Tumor Study Group (GITSG) [7]. In this
study, the combination of bolus 5-fluorouracil (5-FU) and
split course radiation (RT) (total dose, 4000 cGy) was
compared with RT alone or with 6000 cGy combined with
5-FU. A nearly 2-fold increase in median survival (42.2
versus 22.9 weeks) was observed with the regimen of bolus
5-FU and 4000 cGy compared to RTalone.
Subsequent generations of studies have sought to
optimize the use of 5-FU and most contemporary studies
no longer use split-course radiation. Gemcitabine has also
been used as a radiosensitizer and there is evidence to
suggest that concurrent gemcitabine and RT can yield
similar or better outcomes when compared to 5-FU based
CTRT [8]. A number of combination CT regimens with
or without gemcitabine have been tried in LAPC. A recent
systematic review with network meta-analysis of 9989
patients from 23 studies involving 19 different regimes
have demonstrated a statistically significant improvement
in overall survival (OS) and progression free survival (PFS)
relative to gemcitabine [9]. The four drug regimen of folinic
acid, oxaliplatin, irinotecan and 5-FU (FOLFIRINOX)
appears to be the most favored combination with signifi-
cant improvement in OS and PFS compared to most of the
other combinations.
Chen et al. [10] undertook a meta-analysis to evaluate
the long-term clinical efficacy of CTRT over RT or CT
alone in LAPC. Their analysis consisted of data synthesized
from 15 eligible randomized controlled trials of a total of
1128 patients. Of the 15 trials, 12 reported 6-month
survival (n = 964), 14 (n = 1098) reported 12-month survival
while 9 (n = 805) reported survival at 18-months. The
meta-analysis showed that the CTRT group had a superior
survival over the CT or RT group while the 18-month
survival showed no significant difference. Patients on CTRT
had a significantly higher grade 3–4 treatment related
hematological and non-hematological toxicities than those
on CT or RT alone. Thus, the meta-analysis indicates that
CTRT is more efficacious than RT or CT alone and
provides an improvement in OS for patients of LAPC, but
at the cost of increased grade 3–4 toxicities.
In a bid to improve the outcomes in LAPC, erlotinib,
a reversible tyrosine kinase inhibitor acting on the
epidermal growth factor (EGFR) has been also tried
along with CT (gemcitabine). In a recently reported
outcome of the LAP07 international, open label, phase
III randomized study, participants were first randomized
to gemcitabine (n = 223) or gemcitabine with erlotinib
(n = 219). After 4 months of treatment, patients who
were free of any disease progression, underwent a sec-
ond randomization to either continue their CT (n = 136)
or begin CTRT (n = 133) [4]. There was no significant
difference in the overall survival with CTRT compared
with CT alone, nor with gemcitabine versus gemcitabine
plus erlotinib used as maintenance therapy. Moreover,
patients receiving erlotinib experienced added toxicities.
A recently reported systematic review and meta-analysis
of 27 randomized studies consisting of 8205 patients for
targeted therapy for anti-EGFR showed that on pooled
analysis, no significant benefit could be demonstrated in
response rates, OS or PFS with targeted-based therapies
as compared to conventional treatments [11]. Thus, even
the molecular targeted therapies could not get translated
into a better therapeutic benefit in LAPC.
Hyperthermia in combination with chemoradiotherapy as
a therapeutic option
Hyperthermia (HT) at 39–43 °C is a potent radiosensiti-
zer and synergistic to a number of chemotherapeutic
agents, like gemcitabine [12, 13]. In additional to the
various thermoradiobiological interactions that accords a
sensitizing effect to HT, heat also activates dendritic cells
in conjunction with RT or CT. The tumor antigens
derived from the necrotic tumor cells could be taken up
by dendritic cells leading to heat shock protein (HSP)
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mediated induction of immunogenic tumor cells resulting in
immunomodulation, a phenomena mimicking HT induced
"in situ tumor vaccination" [14]. In addition, gemcitabine is
also a known radiosensitizer due to (a) reduced RT induced
DNA repair (b) “S” phase block and (c) triggering of apop-
tosis [15, 16]. Furthermore, HT has been shown to sensitize
the effects of gemcitabine at 43 °C. This has been best ob-
served if gemcitabine is given 24 h after HT [17].
Based on the thermoradiobiological basis of the inter-
action of HT, RT and CT, a number of phase I/II pilot
studies have been undertaken by various institutions.
Most of them have shown improved outcomes with the
above modalities incorporating HT without any signifi-
cant added morbidity or mortality. Patient tolerance has
been reported to be satisfactory [18–22]. In one of the
largest series of 68 patients, 34 evaluable patients were
treated with HT added to CTRT (HTCTRT), while 26
received CTRT alone [18]. At a follow-up of 12-months,
22/34 patients (64.7%) in the HT group and 16/26 patients
(61.5%) in the CTRT group were still alive. The median OS
was 15 months (range: 6–20 months) in the HT group
versus 11 months (range: 5–13 months) in the control
group (p = 0.025). Median time to progression was
11 months (range: 3–16 months). As the study was a
nonrandomized trial and based on patient preferences, the
significant overall survival advantage reported with
HTCTRT over CTRTalone needs cautious interpretation.
A review of the EU Clinical Trials site reveals a list of 109
trials that are currently being investigated by various centers
for “locally advanced pancreatic cancers” [23]. A wide range
of treatment options using gemcitabine, FOLOFIRINOX,
other chemotherapeutic agents as primary therapy, second
line / salvage, neoadjuvant, concurrent with radiotherapy
and adjuvant therapy are under various phase I to III trials.
Only one study is listed in which HT is being explored with
gemcitabine and cisplatinum in patients with locally
advanced or metastatic pancreatic cancer as second-line
therapy after adjuvant or first-line chemotherapy with gem-
citabine or gemcitabine combination (EudraCT Number:
2005–003855-11). The study was activated in June 2006, but
the outcomes are not yet available.
Presently a phase III trial (EudraCT Number: 2008–
004802-14), of adjuvant gemcitabine and capecitabine
versus gemcitabine with cisplatin along with local HT is
ongoing in patients of resectable pancreatic cancers
following a R0 or R1 resection. This trial, “Hyperthermia
European Adjuvant Trial (HEAT)” aims to look for
differences in outcomes following HT added to either of
these two CT regimens [24]. The study is currently open
and recruiting patients. It is a multi-centric trial being
conducted in various centers of Europe, primarily in
Germany. A total of 366 patients is planned to be random-
ized into these two groups following R0/R1 resection. The
endpoint to be evaluated includes OS and PFS.
Thus, as the HEAT study is being conducted in resect-
able pancreatic cancers to explore the likely advantage of
HT added to adjuvant CT, the present HEATPAC study
is primarily for unresectable LAPC. Since most of the
patients of pancreatic cancers in locally advanced stages
are deemed inoperable, it would be of considerable
interest to explore the safety and efficacy of HTCTRT
(with concurrent gemcitabine) compared to CTRT alone
with pre- (as neoadjuvant) and post-intervention FOL-
FIRINOX. The use of HT, RT and gemcitabine is ex-
pected to provide triple sensitization with HT and
gemcitabine both as radiosensitizer and additionally HT
as a sensitizer to gemcitabine. This forms the rationale
of the proposed phase II randomized study (HEATPAC),
comparing HTCTRT versus CTRT in LAPC [25].
Methods and design: HEATPAC study protocol
Study design
This is a phase II randomized study in LAPC (Fig. 1).
Patients of pancreatic cancers fulfilling the following criteria
of “unresectable LAPC” would be considered for this trial.
These include, presence of solid tumor contact with super-
ior mesenteric artery or coeliac axis of >180°, aortic involve-
ment, unreconstructible superior mesenteric vein or portal
vein due to tumor involvement or occlusion due to tumor
or thrombus [26, 27]. All patients who following four cycles
of neoadjuvant FOLFIRINOX on a PET-triple phase CECT
are free of any distant metastasis or gross peritoneal carcin-
omatosis would be randomized to either:
(a)Control group: CTRT with concurrent gemcitabine
and RT or.
(b)Study group: HTCTRT with concurrent
gemcitabine, RT and local HT.
Primary endpoints
1. To determine if HTCTRT following neoadjuvant
and adjuvant CT with FOLFIRINOX would show an
improvement of OS at 1 year from 40% to 60%
compared to concurrent CTRT alone.
2. To assess the acute and the late morbidities
associated with HTCTRT compared to concurrent
CTRT alone.
Secondary endpoints
To compare the progression free survival, local disease
free survival, disease free survival in patients treated
with HTCTRT versus CTRT.
Inclusion criteria
1. Patients of unresectable LAPC as defined above [26, 27].
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2. Histopathologically proven ductal adenocarcinoma
of the pancreas (biopsy/cytology).
3. ECOG performance scale 0 and 1.
4. Age between 18 and 80 years.
5. Absence of distant metastasis or gross peritoneal
carcinomatosis.
6. Adequate kidney functionality defined as creatinine
clearance >50 ml/min.
7. Adequate liver functionality defined as total bilirubin
≤2 times of the upper limit of normal.
8. Adequate bone marrow reserves: WBC count ≥2.5 ×
109/L, platelet count ≥100 × 109/L, hemoglobin
≥8.0 g/L.
9. Women of child-bearing age must secure sufficient
contraception control (dual protection with
condoms and pills) during the clinical trial and 6
months after the clinical trial is completed.
10. For females of child bearing potential, pregnancy
test within 2 week prior to randomization should be
negative.
11. Absence of psychological, familial, sociological or
geographical condition that could potentially
hamper compliance with the study protocol and
follow-up schedule.
12. Ability to travel to Kantonsspital Aarau for weekly
HT. RT and CT could be administered both at
University Hospital Zurich or Kantonsspital Aarau
or other participating institution as per the patient’s
preference.
Exclusion criteria
1. Prior or concurrent malignancies.
2. Patients having metal implants, pacemakers or
clustered markers.
3. Patients with metallic endobiliary stent would need
to be replaced with plastic stents.
4. Any history of myocardial infarction within the past
12 months.
5. Any connective tissue disorder that contraindicate
RT, e.g., scleroderma.
6. Pre-existing grade 2 peripheral neuropathy.
7. Any known contraindication or hypersensitivity to
the chemotherapeutic agents used in the study as
decided by the medical oncologists.
8. Pregnancy, lactation period or lack of reliable
contraception.
9. Any other disease or therapy, which, according to
the investigator, present a risk to the patient or
which are not compatible with the aims of the
clinical trial.
10.Indications that the person concerned will possibly
not keep to the clinical trial plan because of
unwillingness to cooperate or difficulties in keeping
the check-up appointments.
Study interventions: Chemotherapy
All LAPC patients would be receiving neoadjuvant
FOLFIRINOX. It would consist of a 2-h intravenous
Fig. 1 Flow chart of the HEATPAC study protocol. (CT: chemotherapy; RT: radiotherapy; HT: hyperthermia; NACT: neoadjuvant chemotherapy; SIB-IMRT:
simultaneous-integrated boost intensity-modulated radiotherapy; IGRT: image guided radiation therapy; GTV: gross target volume; CTV: clinical target
volume; FOLFIRINOX: calcium folinate, oxaloplatin, irinotecan, 5-FU)
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infusion of oxaliplatin 85 mg/m2, followed by a 2 h
intravenous infusion of calcium folinate 350 mg/m2
concomitantly with 90 min of intravenous infusion of
irinotecan 180 mg/m2, subsequently followed by 5-FU
400 mg/m2 as a bolus and 2400 mg/m2 as a 46 h
continuous intravenous infusion. All patients would
routinely receive ondansetron and dexamethasone with
each cycle for emesis prophylaxis. A total of 4 cycles at 2
weekly intervals would be administered as neoadjuvant CT.
Eight such cycles would be also administered after the com-
pletion of CTRT or HTCTRT. Following the completion of
4 cycles of neoadjuvant FOLFIRINOX, patients would be
randomized to either CTRT or HTCTRT provided there is
no evidence of distant metastasis or gross peritoneal carcin-
omatosis on PET-triple phase CECT scan.
During RT, all patients would receive concurrent gem-
citabine at 400 mg/m2, delivered intravenously over
30 min on day 2 of week 1 to 6 of RT (Fig. 2). Patients
would be closely followed up for any adverse effects and
dose modification would be made at the discretion of
the treating physician based on observed toxicity.
Study interventions: Radiotherapy
RT protocols to be followed in this study have been
adapted as per the Radiation Therapy Oncology Group
(RTOG) protocols, RTOG 0848 and RTOG 1201,
wherever applicable [28, 29]. All patients in both arms
would be planned with simultaneous-integrated boost
intensity-modulated radiation therapy (SIB-IMRT) with
6MV photon or higher and assisted with image guided
radiotherapy. The prescribed RT dose to the 95% of the
gross target volume (GTV) would be 56Gy and 50.4Gy
to the 95% of the clinical target volume (CTV). IMRT
would be delivered 5 days a week at 1.8Gy per fraction.
The maximum dose (Dmax) allowed within the GTV
and CTV to a point that is 0.03cm3 would be 110% of
the prescribed dose to these target volumes provided
that the normal-tissue constraints are met. The mini-
mum dose (Dmin) to the planning target volume (PTV)
to a point, 0.03cm3 would be 95% of the prescribed dose
to these target volumes.
The GTV would consist of primary tumor plus any
regional lymph nodes identifiable on CT / MRI or on
PET-CECT scan. The CTV would be based on the
review of Sun et al. [30] where each lymph nodal region
with risk of involvement of >3% was considered to be a
clinically significant risk and proposed to be considered
as an elective nodal irradiation area. Planning target
volume (PTV) would be defined separately for GTV
(PTV1) and CTV (PTV2). PTV1 will be GTV plus
0.5 cm in all directions while PTV2 would be CTV plus
0.5 cm in all directions when breath-hold, gating or
tracking techniques are used. With free breathing, CTV
to PTV expansion in the cranio-caudal direction will be
based on target motion as assessed by 4D CT scan (but
not exceed 1.5 cm). Expansions in other directions will
be 0.5 cm. The normal tissue dose constraints as
adapted by RTOG 1201 would be considered for this
study [29].
Study interventions: Hyperthermia
HT would be delivered at Kantonsspital Aarau, Aarau,
Switzerland and regular quality assurance would be
carried out in accordance with European Society of
Hyperthermia Oncology (ESHO) quality assurance
guidelines for clinical studies in regional deep HT [31,
Fig. 2 Schematic representation of the study and control arms with chemotherapy, radiotherapy and hyperthermia. (RT: radiotherapy; SIB-IMRT:
simultaneous-integrated boost intensity-modulated radiotherapy; GTV: gross target volume; CTV: clinical target volume)
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32]. Deep HT would be administered by the BSD 2000
unit with the Sigma-60 or Sigma-Eye phased array appli-
cator (M/s Pyrexar Medical, Salt Lake City, Utah, USA).
To define the HT treatment volume with deep hyper-
thermia unit, CT would be carried out in HT treatment
position on the HT planning support (hammock)
adapted for CT. Radiographic markers would be posi-
tioned as for the RT planning CT to define a reference
point, which would be visible in the planning system.
The tumor and the adjacent normal structures would be
contoured in these scans and attempt would be made to
have a similar outline of the target and organs at risk as
in the photon RT plan. The HT treatment planning
target volume would be chosen typically based on the
radiotherapy PTV/CTV and planned using the HT treat-
ment planning, Sigma HYPERPLAN software (M/s Dr.
Sennewald Medizintechnik GmbH, Munich, Germany)
by segmentation and creation of a grid model of the
various body tissues according to their dielectric proper-
ties (e.g., tumor, intestine, abdominal organs, muscle,
bone, fat) followed by simulation of the electric fields.
The Sigma HYPERPLAN, version 2.0, has specific perfu-
sion factors for each tissue type that takes into account
the blood circulation in the tissue (Fig. 3). The above
structures would be defined individually during the con-
touring and thermal treatment planning. Using appropri-
ate power and steering parameters, a specific absorption
rate distribution in the target volume would be gener-
ated using finite element modeling. A warm-up heating
phase of 30 min followed by 60 min of HT treatment
would be used.
As per the ESHO guidelines for thermal mapping and
to ensure quality assurance in HT treatment [31, 32],
prior to each HT treatment, a multi-sensor thermometry
probe (FISO, FISO Technologies Inc. Quebec, Canada)
would be inserted endoscopically to cross beyond the
duodenum such that the temperature measuring sensors
are along the duodenal part encircling the pancreas. The
probe having a length of 115 cm has a diameter of
870 μm and fits into a 6F catheter. The 8 sensors are
spaced at every 2 cm which would be used for online
temperature monitoring. Check films would be taken to
verify the position of the temperature probe. Attempts
would be made to attain a temperature of 40–43 °C
taking into consideration individual patient tolerance to
hyperthermia (Fig. 3). Temperature mapping would be
carried out with a mapping interval of 5–10 min. The
total treatment period would consist of the heating
period (until the target temperature is reached,
maximum 30 min) and thereafter the therapy period
(target temperature maintained for 60 min).
Patients would be instructed to mention any unpleas-
ant sensation suggesting a hot spot, such as a burning
sensation, a feeling of pressure, or any pain. By switching
off the power briefly (30 s), it would be established if the
pain was caused by the radiated power. Accordingly the
treatment settings (phase and amplitude) would be
adjusted, or water cooling bags applied for complaints
on the skin surface. For pain caused by the tumor or
positioning in the applicator, analgesics might be given.
Following each HT treatment, the thermometry probes
would be removed. The procedure would be repeated
Fig. 3 Workflow of the HEATPAC study protocol for patients’ to be treated with thermochemoradiotherapy. (FOLFIRINOX: calcium folinate,
oxaloplatin, irinotecan, 5-FU)
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for each weekly HT sessions during the entire course of
treatment.
Evaluation of endpoints
All patients would be closely monitored during the en-
tire course of the study for any potential adverse event.
All adverse events either observed by the physician and/
or reported by the patient will be documented as per the
“Common Terminology Criteria for Adverse Events”
(CTCAE) guidelines, version 4.03 [33].
Response to SIB-IMRT and HT will be carried out by
comparing tumor size at the time of registration for the
study with measurements taken 4 weeks after comple-
tion of RT. Response will be measured through radio-
logical imaging by triple phase CECT. MRI with or
without PET-CT would be optional, but not used for
loco-regional response scoring. The response would be
evaluated as per the revised “Response Evaluation
Criteria in Solid Tumors” (RECIST, version 1.1) [34].
The survival end points would be evaluated during the
entire study period. Overall survival represents the time
from date of registration (at the point of randomization)
to the time of death from any cause during the entire
study period. Patients surviving at the end of study
period would be considered as “survivors” for computa-
tion of the overall survival. Death from any cause would
be considered as an “event” for Kaplan-Meier estimations.
Patients will be followed until the study ends (4.5 years
from date of approval from Ethical Commissions). The
other evaluable secondary endpoints would include
progression free survival, local disease free survival and
disease free survival. At the conclusion of the study, the
survival endpoints would be evaluated by univariate and
multivariate analysis to look for any potential risks and
predictive parameters.
Sample size considerations
One-year overall survival (death from any cause) would be
considered as the primary endpoint for the study. The
period of survival would be computed from the date of
randomization into the HEATPAC protocol to the last fol-
low up or date of death from any cause. The 1-year survival
rate with CTRT is considered as 40% (p0 = 40%). With
HTCTRT, an overall survival advantage of +20% is ex-
pected (p1 = 60%). The sample size calculations were based
on Simon’s two-stage minimax design [35] with α = 0.05
and β = 80%. Assuming a drop-out rate of 10%, a total of
maximum 86 patients would be divided in the 2 groups of
HTCTRTand CTRT of 43 patients each (39 + 4) (Fig. 4).
Trial registration, ethical and legal considerations
The study is registered with the ClinicalTrials.gov
(NCT02439593) and has been approved by the Ethical
Commissions of Basel and Zurich, Switzerland [25]. All
patients enrolled for the study would be required to
furnish an informed consent. The responsible investiga-
tor will ensure that this study is conducted in agreement
with the Declaration of Helsinki and conducted accord-
ing to the ICH Harmonized Tripartite Guideline for
Good Clinical Practice. Patient confidentiality would be
maintained and the patient data would be available only
to nominated co-investigators of the HEATPAC study
group. During the course of the study the investigator’s
site will be visited periodically and relevant documents
would be available for review by the independent moni-
tors of the trial.
Sponsorship
The study has been jointly sponsored by the Radiation
Oncology Centre KSA-KSB, Kantonsspital Aarau,
Switzerland and Clinic for Oncology, University Hospital
Zurich, Switzerland.
Fig. 4 Sample size calculations for the HEATPAC study as per the Simon’s two-stage minimax design [35]. (OS: overall survival; CTRT: chemoradiotherapy;
HTCTRT: thermochemoradiotherapy)
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Discussion
Following the demonstrated biological rationale of
hyperthermia, there has been resurgence of using HT in
clinics. HT unlike other forms of anticancer therapies
(like RT and CT), is well tolerated, safe and without any
significant acute or late toxicities. It’s one of the most
potent radiosensitizer and also exhibits thermal syner-
gism to a number of CT agents. HT is thus a unique
therapeutic modality and has been shown to improve
the therapeutic outcomes in a wide range of malignan-
cies. These include - locally recurrent breast cancers,
locally advanced head and neck cancers, locally advanced
cancer cervix, soft tissue sarcoma, melanoma, pelvic tumors
and others [12, 36–39]. Further, HT has also been shown to
be a potential immunomodulating agent when used with
RT [14]. It therefore certainly deserves to be explored along
with the standard treatment modalities of CT and RT, espe-
cially in those disease sites where the standard therapeutic
approaches of CT and RT have failed to provide significant
improvements in outcomes.
The outcomes for LAPC have remained poor and even
with various schedules of radiotherapy, chemotherapy
and even targeted agents, patients continue to have a
grim outlook. Thus, LAPC with its fatal outcome is one
of the ideal disease situations where HT in combination
with CTRT needs to be evaluated in a randomized
setting. Since most of the patients diagnosed with pan-
creatic cancer present as locally advanced disease (which
are primarily inoperable), the proposed study is designed
to explore the efficacy of local HT along with the con-
ventional CTRT as a phase II randomized trial in LAPC.
An ongoing phase III trial, HEAT of adjuvant gemcita-
bine or gemcitabine with cisplatinum along with local HT
has therefore been initiated as an adjuvant therapy in
patients of resectable pancreatic cancers following a R0 or
R1 resection [24]. To date, there has been no randomized
study conducted or reported using HT in LAPC.
Conclusion
The present phase II randomized study, HEATPAC with
triple sensitization of concurrent HTCTRT along with
pre-and post-interventional FOLFIRINOX could provide
a potentially useful therapeutic option in LAPC. Based on
the strong thermoradiobiological basis and its potentiation
with concurrent CTRT, the outcomes are expected to be
in favor with HT combined with CTRT. This could pave
the way for a future phase III clinical trial in LAPC.
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